Question: Did the JG 77 battle the same enemies during the Balkans campaign and the invasion of Crete? Passage 1:The phenomenon of a government in exile predates the formal utilization of the term. In periods of monarchical government, exiled monarchs or dynasties sometimes set up exile courts—as the House of Stuart did when driven from their throne by Oliver Cromwell and again at the Glorious Revolution (see ). The House of Bourbon would be another example because it continued to be recognized by other countries at the time as the legitimate government of France after it was overthrown by the populace during the French Revolution. This continued to last through the rule of Napoleon Bonaparte and the Napoleonic Wars from 1803–04 to 1815. With the spread of constitutional monarchy, monarchical governments which were exiled started to include a prime minister, such as the Dutch government during World War II headed by Pieter Sjoerds Gerbrandy.
 Passage 2:Woldenga's career started as a captain in the merchant marine. He started his flight training in 1928 and worked as chief pilot for the FVK Warnemünde. He transferred to the newly emerging Luftwaffe, taking command as Gruppenkommandeur of the I./Jagdgeschwader 131 (JG 131) — later renamed to I./Jagdgeschwader 1 (JG 1) — on 1 April 1937. With this unit he participated in the invasion of Poland in 1939. He surrender command of the Gruppe on 1 February 1940 and was transferred to the Reichsluftfahrtministerium. He briefly led Jagdgeschwader 27 (JG 27) on the Channel Front from 11 October to 22 October 1940 before he was made Geschwaderkommodore of Jagdgeschwader 77 (JG 77). Under this command, JG 77 participated in the Balkans Campaign and invasion of Crete. JG 77 claimed 50 aerial victories. Woldenga received the Knight's Cross of the Iron Cross. He commanded of JG 27 on 21 June 1941 during the invasion of the Soviet Union and claimed 4 aerial victories. He relocated the Geschwaderstab to North Africa in December 1941. He was appointed Fliegerführer Balkan on 10 June 1942. His last service position of the war was commander of the Luftkriegschule 10 in Fürstenwalde near Berlin. He is credited with three aerial victories of which two were claimed on the Eastern Front.
 Passage 3:He attended the Pennsylvania State University and obtained his M.D. degree from Harvard Medical School in 1947. He interned at the Hospital of the University of Pennsylvania. From 1948 to 1952 he was a post-doctoral fellow in the Department of Physiological Chemistry at the University of Pennsylvania School of Medicine and fellow in clinical medicine in the Department of Medicine. In collaboration with Samuel Gurin at the University of Pennsylvania, Brady discovered the enzyme system for the biosynthesis of long chain fatty acids, and later discovered the role of malonate coenzyme A in this process. After two and one-half years on active duty in the U.S. Naval Medical Corps, he joined the National Institutes of Health in 1954. He was Chief of the Developmental and Metabolic Neurology Branch in the National Institute of Neurological Disorders and Stroke from 1972 to 2006. Dr. Brady and his colleagues identified the enzymatic defects in Gaucher's disease, Niemann–Pick disease, Fabry disease and the specific metabolic abnormality in Tay–Sachs disease. He and his associates developed diagnostic, carrier detection, prenatal tests for these conditions, and effective enzyme replacement therapy for patients with Gaucher disease and Fabry disease. These were the first-ever enzyme replacement therapy (ERT) treatments for lysosomal diseases, and directly led to great advances in the development of enzyme replacement therapies for some of the other lysosomal diseases, by many different researchers who were inspired by Dr. Brady. (An international research and development effort for new ERT for several devastating lysosomal diseases continues today at an intense pace, and numerous ERT clinical trials are underway.) Late in his life, Dr. Brady was investigating substrate depletion, molecular chaperone therapy, and gene therapy for patients with metabolic storage disorders.

Output: 2